EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
February 27 2024 - 6:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to help improve the
lives of patients with retinal diseases, today announced that
Company management will participate at the following upcoming
conferences:
- TD Cowen
44th Annual Healthcare
Conference
Forum: Fireside
ChatDate: Tuesday, March 5, 2024Time: 10:30 a.m. ET
- Leerink Partners Global
Biopharma Conference
Forum: 1x1 Investor
MeetingsDate: Monday, March 11, 2024
- Guggenheim
5th Annual Healthy Altitudes
Summit
Forum: Fireside
ChatDate: Wednesday, March 13, 2024Time: 9:15 a.m. ET
A webcast and subsequent archived replay of the
presentations may be accessed via the Investors section of the
Company website at www.eyepointpharma.com.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage biopharmaceutical company committed to developing
and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company's pipeline
leverages its proprietary bioerodible Durasert E™ technology for
sustained intraocular drug delivery. The Company’s lead product
candidate, EYP-1901, is an investigational sustained delivery
treatment for VEGF-mediated retinal diseases combining vorolanib, a
selective and patent-protected tyrosine kinase inhibitor with
Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2
agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to
potentially improve outcomes in serious retinal diseases. The
proven Durasert® drug delivery technology has been safely
administered to thousands of patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by
Equinox Sciences, a Betta Pharmaceuticals affiliate, for the
localized treatment of all ophthalmic diseases outside of China,
Macao, Hong Kong and Taiwan.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2024 to May 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From May 2023 to May 2024